Hosted on MSN24d
Beam upgraded by Bernstein ahead of AATD dataBernstein has upgraded Beam Therapeutics (NASDAQ:BEAM) to outperform from market perform, citing upcoming data on the company’s drug candidate for alpha-1 antitrypsin deficiency, or AATD.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback